MX340792B - Sal amorfa de un inhibidor macrociclico de virus de hepatitis c. - Google Patents

Sal amorfa de un inhibidor macrociclico de virus de hepatitis c.

Info

Publication number
MX340792B
MX340792B MX2011008999A MX2011008999A MX340792B MX 340792 B MX340792 B MX 340792B MX 2011008999 A MX2011008999 A MX 2011008999A MX 2011008999 A MX2011008999 A MX 2011008999A MX 340792 B MX340792 B MX 340792B
Authority
MX
Mexico
Prior art keywords
hcv
amorphous salt
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
MX2011008999A
Other languages
English (en)
Other versions
MX2011008999A (es
Inventor
Roger Petrus Gerebern Vandecruys
Kock Herman De
Remoortere Peter Jozef Maria Van
Original Assignee
Ortho-Mcneil-Janssen Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340792(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho-Mcneil-Janssen Pharmaceuticals Inc * filed Critical Ortho-Mcneil-Janssen Pharmaceuticals Inc *
Publication of MX2011008999A publication Critical patent/MX2011008999A/es
Publication of MX340792B publication Critical patent/MX340792B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a la forma amorfa de la sal de sodio del inhibidor macrocíclico de HCV de la fórmula: (ver fórmula (I)) así como procedimientos para fabricar esta sal.
MX2011008999A 2009-02-27 2010-02-26 Sal amorfa de un inhibidor macrociclico de virus de hepatitis c. MX340792B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09153964 2009-02-27
PCT/EP2010/001197 WO2010097229A2 (en) 2009-02-27 2010-02-26 Amorphous salt of a macrocyclic inhibitor of hcv

Publications (2)

Publication Number Publication Date
MX2011008999A MX2011008999A (es) 2011-09-26
MX340792B true MX340792B (es) 2016-07-25

Family

ID=40756982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008999A MX340792B (es) 2009-02-27 2010-02-26 Sal amorfa de un inhibidor macrociclico de virus de hepatitis c.

Country Status (26)

Country Link
US (2) US9321758B2 (es)
EP (2) EP3150596A1 (es)
JP (2) JP5711672B2 (es)
KR (2) KR101713066B1 (es)
CN (2) CN104478868A (es)
AU (1) AU2010219160B2 (es)
BR (1) BRPI1008918A2 (es)
CA (2) CA2753667C (es)
CY (1) CY1119121T1 (es)
DK (1) DK2401272T3 (es)
ES (1) ES2616603T3 (es)
HK (2) HK1166315A1 (es)
HR (1) HRP20170214T1 (es)
HU (1) HUE031738T2 (es)
IL (2) IL214398A0 (es)
LT (1) LT2401272T (es)
MX (1) MX340792B (es)
NZ (1) NZ594403A (es)
PL (1) PL2401272T3 (es)
PT (1) PT2401272T (es)
RU (1) RU2536868C2 (es)
SG (2) SG2014008981A (es)
SI (1) SI2401272T1 (es)
SM (1) SMT201700121B (es)
WO (1) WO2010097229A2 (es)
ZA (1) ZA201106303B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
SI2401272T1 (sl) * 2009-02-27 2017-04-26 Janssen Pharmaceuticals, Inc. Amorfna sol makrocikličnega inhibitorja VHC
EP2907505A3 (en) * 2011-12-29 2015-12-30 Abbvie Inc. Solid compositions comprising an HCV inhibitor
US9034832B2 (en) * 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CN104780921A (zh) * 2012-08-31 2015-07-15 杨森制药公司 Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合
LT2950786T (lt) * 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
CN105228593B (zh) * 2013-03-15 2018-08-28 勃林格殷格翰国际有限公司 呈无定形状态的hcv抑制剂的固体口服剂型
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
WO2015109925A1 (zh) * 2014-01-21 2015-07-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2016054240A1 (en) * 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
WO2017017604A1 (en) 2015-07-27 2017-02-02 Lupin Limited Substantially pure amorphous simeprevir sodium salt and the process for preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
CN1889970B (zh) * 2003-10-14 2012-06-13 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
AU2005214469A1 (en) * 2004-02-24 2005-09-01 Siegfried Generics International Ag Pharmacologically acceptable salts of clopidogrel
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
UA91677C2 (ru) * 2004-03-30 2010-08-25 Интермюн, Инк. Макроциклические соединения как ингибиторы вирусной репликации
US20080146809A1 (en) * 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
PE20070343A1 (es) 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP2008115173A (ja) 2006-10-13 2008-05-22 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物の塩およびそれらの結晶ならびに非晶質体
US8399434B2 (en) 2006-11-08 2013-03-19 Duke University Method of activation of oxazaphosphorines
ATE467630T1 (de) * 2007-02-01 2010-05-15 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
CN101589040A (zh) * 2007-02-01 2009-11-25 泰博特克药品有限公司 Hcv巨环抑制剂的多晶形
EP2185516A2 (en) 2007-08-29 2010-05-19 Pfizer Products Incorporated Polymorphs of 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid sodium salt or a hydrate thereof and methods for making the same
SI2401272T1 (sl) * 2009-02-27 2017-04-26 Janssen Pharmaceuticals, Inc. Amorfna sol makrocikličnega inhibitorja VHC

Also Published As

Publication number Publication date
RU2536868C2 (ru) 2014-12-27
HRP20170214T1 (hr) 2017-04-07
CA2898529C (en) 2017-10-17
EP3150596A1 (en) 2017-04-05
LT2401272T (lt) 2017-03-27
WO2010097229A3 (en) 2010-11-11
US20110306634A1 (en) 2011-12-15
US9321758B2 (en) 2016-04-26
SG173772A1 (en) 2011-09-29
CA2753667C (en) 2015-11-17
DK2401272T3 (en) 2017-02-27
ZA201106303B (en) 2013-02-27
RU2011139325A (ru) 2013-04-10
US20160251345A1 (en) 2016-09-01
NZ594403A (en) 2013-07-26
EP2401272B1 (en) 2017-01-11
CN104478868A (zh) 2015-04-01
PL2401272T3 (pl) 2017-06-30
SMT201700121B (it) 2017-03-08
HK1208464A1 (en) 2016-03-04
SG2014008981A (en) 2014-04-28
CY1119121T1 (el) 2018-02-14
SI2401272T1 (sl) 2017-04-26
PT2401272T (pt) 2017-02-28
CA2898529A1 (en) 2010-09-02
KR20110123273A (ko) 2011-11-14
KR101713066B1 (ko) 2017-03-07
IL214398A0 (en) 2011-09-27
JP2015143240A (ja) 2015-08-06
JP6214584B2 (ja) 2017-10-18
HUE031738T2 (en) 2017-07-28
MX2011008999A (es) 2011-09-26
JP5711672B2 (ja) 2015-05-07
IL243058A0 (en) 2016-02-29
BRPI1008918A2 (pt) 2016-03-15
CA2753667A1 (en) 2010-09-02
EP2401272A2 (en) 2012-01-04
ES2616603T3 (es) 2017-06-13
AU2010219160A1 (en) 2011-08-25
CN102356080B (zh) 2015-04-29
KR20170026660A (ko) 2017-03-08
JP2012519158A (ja) 2012-08-23
CN102356080A (zh) 2012-02-15
HK1166315A1 (en) 2012-10-26
KR101868412B1 (ko) 2018-06-18
WO2010097229A2 (en) 2010-09-02
AU2010219160B2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
MX2011008999A (es) Sal amorfa de un inhibidor macrociclico de virus de hepatitis c.
IN2012DN02751A (es)
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
MY164776A (en) Heterocyclic compound
MY158982A (en) Heterocyclic compound
CR20120295A (es) Triazolopiridinas
SG10201407927UA (en) Imidazopyridine derivatives as jak inhibitors
BRPI1012770B8 (pt) derivados de tiofeno
UY32481A (es) Derivados de benzofurano
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
IN2014CN04449A (es)
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
AP2010005509A0 (en) Salts of HIV inhibitor compounds.
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
IN2012DN05081A (es)
PL2430002T3 (pl) Sposób wytwarzania związku przydatnego jako inhibitor TAFI
CY1111573T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
MX2011013676A (es) Forma cristalina de pemirolast.
IN2012DN03104A (es)
UA102816C2 (ru) Способ синтеза кристаллической формы v агомелатина
WO2012150183A8 (en) Crystalline sodium salt of an hiv integrase inhibitor
MX2013002656A (es) Nuevo proceso.
WO2008061238A3 (en) Processes for production of 4-biphenylyazetidin-2-ones
MX2009005977A (es) Polimorfos de motilida.
IN2013MN01107A (es)

Legal Events

Date Code Title Description
FG Grant or registration